What's encouraging, however, is that there may be more benefits with GLP-1 drugs than simply losing weight and controlling ...

Powerful new weight-loss medications are in the works to treat obesity. Doctors explain why more options are needed and the ...

Novo Nordisk ( NVO +1.68%) was once the top player in the weight loss drug market. The company's medicine, Wegovy, ...

Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in ...

Eli Lilly’s Mounjaro is the only dual drug on the market, targeting GLP-1 and GIP. Doctors say that Mounjaro is also more ...

Eli Lilly highlighted 2025 as the rollout year for obesity drugs, with Mounjaro at the forefront of its weight-loss portfolio ...

Eli Lilly looks undervalued as earnings forecasts rise and GLP-1 catalysts near. Read the full analysis here of LLY stock.

Eli Lilly working Humana to distribute obesity medications through employer-focused programs via CenterWell Pharmacy.

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

Its lineup and pipeline put it well ahead of even its closest competitor. The drugmaker should continue riding this wave for the foreseeable future. Over the past few years, Eli Lilly (NYSE: LLY) has ...

Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has ...

Drugmakers Eli Lilly and Novo Nordisk have been sued in Texas by a compounding pharmacy that alleges they are illegally ...